Drug Profile

NLM 001

Alternative Names: NLM-001; TAK-441

Latest Information Update: 19 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Millennium
Developer Millennium; Nelum
Class Antineoplastics; Pyridones; Pyrroles; Small molecules
Mechanism of Action Hedgehog protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Pancreatic cancer
Discontinued Medulloblastoma; Solid tumours

Most Recent Events

19 Dec 2024 Nelum in-licenses NLM 001/TAK 441 from Takeda Oncology (Nelum pipeline, December 2024)
23 Jan 2023 Discontinued - Phase-I for Medulloblastoma in USA (PO) before January 2023 (Agenus pipeline, January 2023)
01 Sep 2021 Phase-I/II clinical trials in Pancreatic cancer (Combination therapy, First-line therapy, Late-stage disease) in Spain (PO) (NCT04827953)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com